Send to
Editors
NICE Guideline Updates Team (UK).
Source
London: National Institute for Health and Care Excellence (UK); 2019 Nov.
National Institute for Health and Care Excellence: Clinical Guidelines.
Excerpt
This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.
Copyright © NICE 2019.
Sections
- Guidance
- [A]. Evidence review for intractable nausea and vomiting
- [B]. Evidence review for chronic pain
- [C]. Evidence review for spasticity
- [D]. Evidence review for epilepsy
- [E]. Evidence reviews for prescribing cannabis-based medicinal products
- Appendix 1. Expert witness report – Cannabinoid Psychopharmacology – Tom Freeman, Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath
- PMID: 31909928
